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Telomere dysfunction and fusion can drive genomic instability and clonal evolution in hu-
man tumours, including breast cancer. Telomere length is a critical determinant of telo-
mere function and has been evaluated as a prognostic marker in several tumour types,
but it has yet to be used in the clinical setting. Here we show that high-resolution telomere
length analysis, together with a specific telomere fusion threshold, is highly prognostic for
overall survival in a cohort of patients diagnosed with invasive ductal carcinoma of the
breast (n ¼ 120). The telomere fusion threshold defined a small subset of patients with
an extremely poor clinical outcome, with a median survival of less than 12 months
(HR ¼ 21.4 (7.9e57.6), P < 0.0001). Furthermore, this telomere length threshold was inde-
pendent of ER, PGR, HER2 status, NPI, or grade and was the dominant variable in multivar-
iate analysis. We conclude that the fusogenic telomere length threshold provides a
powerful, independent prognostic marker with clinical utility in breast cancer. Larger pro-
spective studies are now required to determine the optimal way to incorporate high-
resolution telomere length analysis into multivariate prognostic algorithms for patients
diagnosed with breast cancer.
ª 2015 The Authors. Published by Elsevier B.V. on behalf of Federation of European
Biochemical Societies. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction inform on treatment options and to provide prognostic infor-The clinicalmanagement of breast cancer is informed by prog-
nostic and predictive markers, which allow breast tumours to
be classified into subtypes that can display distinct clinical
outcomes. These markers include histopathological criteria
such as tumour size, grade and lymph node metastasis: as
well as the molecular markers, such as oestrogen receptor
(ER) and progesterone receptor (PGR), that predict response to
treatment with endocrine therapy, or human epidermal
growth factor receptor 2 (HER2) that predicts response to
HER2 antagonists (Subramaniam and Isaacs, 2005). These
data are used in combination with multivariate algorithms to7 038.
.M. Baird).
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5), http://dx.doi.org/10.1mation (Mook et al., 2009). These markers can be augmented
by gene expressionprofiling that has allowed the identification
of additional molecular subtypes, which can inform about
treatment options in specific clinical subsets (Hennessy
et al., 2009).Whilst thesemarkers can inform the clinicalman-
agement of breast cancer, they are unable to provide definitive
individualised prognostic information.
Whole genome sequence analysis of breast tumours has
revealed further levels of genetic heterogeneity that can
impact on clinical outcome, it is apparent from these studies
that increasing genomic complexity confers a poorer prog-
nosis (Curtis et al., 2012). The underlying mechanisms drivingf Federation of European Biochemical Societies. This is an open
censes/by/4.0/).
usion threshold identifies a poor prognostic subset of breast
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Table 1 e Clinical characteristics of the invasive ductal breast
carcinoma cohort (n[ 120).
Factor Subset Number
Median age 60.5 years
Range 33e87 years
Median follow-up 4.6 years
Grade I 11
II 47
III 62
ER status negative 30
positive 89
not determined 1
PGR status negative 36
positive 41
not determined 43
NPI status <3.4 14
>3.4/<5.4 37
>5.4 18
not determined 51
HER2 status negative 78
positive 27
not determined 15
Adjuvant chemotherapy negative 39
positive 81
Adjuvant radiotherapy negative 31
positive 89
Adjuvant hormone therapy negative 26
positive 91
unknown 3
ER ¼ estrogen receptor.
PGR ¼ progesterone receptor.
NPI ¼ Nottingham Prognostic Index.
HER2 ¼ human epidermal growth factor receptor 2.
M O L E C U L A R O N C O L O G Y XXX ( 2 0 1 5 ) 1e82genomic instability and selection for complex genomes in
breast cancer is not entirely clear, but likely includes DNA
repair and checkpoint defects, as well as telomere dysfunc-
tion (Kwei et al., 2010). Telomeres are structures that cap
the ends of chromosomes and prevent aberrant repair of
the natural chromosome end by the DNA double strand break
repair apparatus (de Lange, 2005). Telomere erosion, as a
function of cell division, can lead to the formation of short
dysfunctional telomeres that have lost the end-capping func-
tion and are capable of fusion with other telomeres or non-
telomeric loci (Capper et al., 2007; Counter et al., 1992). The
presence of short dysfunctional telomeres, which are capable
of fusion and associated with genomic complexity, have been
detected in many tumour types, including breast cancer
(Chin et al., 2004; Lin et al., 2010; Roger et al., 2013). These
data are consistent with tumour cells undergoing a period
of ‘telomere crisis’ during the progression to malignancy,
which drives large-genomic rearrangements and creates the
diversity on which clonal selection can operate. Telomere
dysfunction and fusion may represent a common mecha-
nism of genomic instability facilitating progression in a broad
range of tumour types.
Importantly, short dysfunctional telomeres have been
detected in early-stage tumours (Lin et al., 2010; Meeker
et al., 2004b), as well as in premalignant lesions. This indicates
that telomere dysfunction can precede disease progression
and is not simply a biomarker of advanced disease. Indeed,
recent evidence suggests that short telomeres may be an
inherent property of a proportion of cells in which the tumour
initiating event occurred (Roger et al., 2013). Telomere length
in early stage lesions varies considerably between different
tumour clones, leading to the hypothesis that clones harbour-
ing short dysfunctional telomeres exhibit a mutator pheno-
type that can drive clonal evolution and progression:
whereas those exhibiting longer telomeres, may have a
more stable genome and be less prone to clonal evolution
(Roger et al., 2013). Thus, by informing on the propensity of a
tumour to undergo clonal evolution, the telomere length of
early-stage tumours, has the potential to provide prognostic
information. We have recently examined this hypothesis in
chronic lymphocytic leukaemia (CLL), in which we had previ-
ously identified that telomere shortening and dysfunction can
occur prior to clinical progression (Lin et al., 2010). We estab-
lished the telomere length threshold below which telomere
fusion could be detected and we used this to stratify patients
based on telomere length (Lin et al., 2014). These data show
that telomere lengths below the fusion threshold are highly
prognostic and that the mean of the fusogenic range
(2.26 kb) provided the optimum prognostic resolution. Indeed,
telomere length below the fusion threshold was the most
powerful predictor of survival in CLL and this was particularly
prognostic in early-stage patients (HR ¼ 19.3 (17.8e802.5),
P < 0.0001) (Lin et al., 2014). Given the prognostic significance
of our findings in CLL and that telomere dysfunction has been
implicated in many tumour types, we wanted to establish
whether our threshold for telomere dysfunction could predict
outcome in other common solid human cancers. Here we
show that the telomere fusion threshold, established in CLL,
identifies a subgroup of breast cancer patients with an
extremely poor clinical outcome.Please cite this article in press as: Simpson, K., et al., Telomere f
cancer patients, Molecular Oncology (2015), http://dx.doi.org/10.12. Materials and methods
2.1. Breast cancer cohort
DNA samples extracted from frozen tissue blocks obtained
from surgically resected Invasive Ductal carcinoma of the
breast were obtained with ethical approval from the Wales
Cancer Bank. A certified histopathologist determined percent-
age tumour in each section as detailed in Supplementary
Table 1. DNA extraction was performed using the Qiagen Tis-
sueLyser to homogenize the tissue and the QIAamp DNAmini
kit (Qiagen, Cat#: 51306) according to the manufacturers
guidelines. The median follow-up of the cohort was 4.6 years
and the patients’ clinical/laboratory characteristics are sum-
marized in Table 1 and provided in full in Supplementary
table 1.
2.2. Telomere length analysis
For telomere length analysis at the XpYp telomerewe used the
single telomere length analysis (STELA) assay as previously
described (Baird et al., 2003; Capper et al., 2007); for three sam-
ples that displayed bimodal telomere length distributions, we
used the mean of lower modal distribution.usion threshold identifies a poor prognostic subset of breast
016/j.molonc.2015.02.003
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Figure 1 e Telomere dysfunction is highly prognostic in breast cancer. (A) An example of XpYp STELA in 5 breast cancer samples. (B) Mean
telomere length in a cohort of patients diagnosed with ductal breast carcinoma (n [ 120), telomere length was determined using single telomere
length analysis (STELA). The telomere length thresholds that provide prognostic information are indicated with coloured lines, the upper limit
3 kb (pink) and the optimum limit of 2.26 kb (purple). (C) Kaplan Meier curve for overall survival (OS) using the median telomere length of the
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Statistical analysis including the ManneWhitney and Chi
squared tests were carried out using Prism 6.0 (Graphpad),
SPSS version 20 (IBM) and SAS version 9.3 software (SAS Insti-
tute). Univariate comparisons for overall survival (OS) were
conducted with the log-rank test, displayed as Kaplan Meier
curves and hazard ratios calculated using the cox proportional
hazards model. Analyses of time to event outcomes with
respect to continuous variables or those with less than two
categories, together with multivariable analyses, were per-
formed using a Cox proportional hazard model with forward
selection. P < 0.05 was considered significant. Hazard Ratio
(HR).3. Results
Weperformed high-resolution single telomere length analysis
(STELA) on DNA obtained from 120 tumour samples from pa-
tients diagnosed with invasive ductal carcinoma of the breast
with a median follow-up of 4.6 years (Table 1). STELA is
capable of detecting the full spectrum of telomere lengths at
specific chromosome ends (Baird et al., 2003), of particular
importance is its ability to detect the presence of short telo-
meres within the length ranges at telomeres are capable of
fusion (Figure 1A; (Capper et al., 2007). Consistent with previ-
ous reports, telomere length of the tumour samples was not
associated with age (r2 ¼ 0.009) (Martinez-Delgado et al.,
2013). There was marked heterogeneity in the mean telomere
length distributions between patients ranging from 1.07 kb to
9.97 kb (median 3.98 kb). 8/120 (7%) of the cohort displayed
telomere length distributions of less than the 2.26 kb fusion
threshold (Figure 1B). Stratification of the cohort based on
themedian telomere length provided no prognostic resolution
(P¼ 0.73; Figure 1C). In contrast, the optimum fusion threshold
(2.26 kb), identified in CLL, was a strong predictor of overall
survival (P < 0.0001; HR ¼ 21.4 (7.9e57.6), Figure 1D). Patients
with telomere lengths below the threshold displayed a me-
dian survival of 348 days (95% CI 233e1760) whereas patients
above the threshold showed 89% (95% CI 80%e94%) survival
at 60 months.
Recursive partitioning based on incremental telomere
length thresholds revealed that the 2.26 kb threshold provided
the optimal prognostic resolution (Figure 1E). However, it was
also apparent that longer telomere length thresholds, within
the fusogenic range, were also highly prognostic (Figure 1E).
For example 11% of the cohort display mean telomere length
profiles of less than 2.6 kb; this threshold was also highly pre-
dictive of clinical outcome (P < 0.0001; HR ¼ 9.0 (3.6e22.6);
Figure 1F). The longest telomere length that still provided sig-
nificant prognostic resolution was 3 kb, which equated to thecohort to stratify patients. Telomere Length (TL) used to stratify patients, P
on the plots together with numbers at risk in each arm (N). (D) Kaplan Meie
patients. (E) Recursive partitioning of mean telomere length in the same co
for the entire cohort; 2.26 kb provided the optimal discrimination in this br
black markers indicate non-significant differences (P> 0.05). (F) Kaplan
stratify patients.
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cancer patients, Molecular Oncology (2015), http://dx.doi.org/10.1lower quartile of telomere length distributions within the
cohort (P < 0$035; HR ¼ 2.7 (1.1e6.7); Figure 1B and E).
The fusion thresholdwas significantlymoreprognostic than
theestablishedclinical and laboratorymarkers evaluated in the
same cohort (Figure 2). No relationship was detected between
telomere length and the status of the commonly used prog-
nosticmarkers (Figure 3AeD). Furthermore, patientswith short
telomeres (<3.0 kb)wereobserved inall of the establishedprog-
nostic subsets, including estrogen receptor (ER), progesterone
receptor (PGR) and human epidermal growth factor receptor 2
(HER2) positive and negative subsets (Figure 3AeC), as well as
in all 3 histopathologic grades (Figure 3D) and NPI score
(Figure 3E). Categorisation of breast tumours into sub-types
based on ER, PGR, HER2 expression patterns revealed no statis-
tically significant differences in the overall telomere length dis-
tributions or the proportions of tumours with telomere lengths
within the length range that provides prognostic significance
(Figure 3F). These data indicate that the poor prognosis of pa-
tients with tumours exhibiting short telomeres is independent
of the established markers used in breast cancer. This was
confirmed inmultivariate analysis using Cox proportional haz-
ards with forward selection. The multivariate analysis showed
that, despite the relevantly small number of patients fully char-
acterised for all the establishedmarkers (Table 1), the telomere
fusogenicmeanwas themost significant parameter for survival
(P < 0.0001; HR ¼ 8.1 (6.2e12.7)); no other parameters met the
P < 0.05 level for entry into the model including age, Notting-
ham prognostic index, oestrogen receptor status, progesterone
receptor status, tumourgradeandHER2status. Thesedata indi-
cate the potential of high-resolution telomere length analysis
for the stratification of patientswith breast cancer; a larger vali-
dation cohort is required to substantiate these findings.4. Discussion
The underlying molecular mechanisms that result in the
large-scale genomic aberrations observed in some breast can-
cer subtypes are not clear (Kwei et al., 2010); however there is
evidence to implicate telomere dysfunction in this process. In
commonwithmany solid tumours, telomere erosion has been
documented in breast cancer (Odagiri et al., 1994) and evi-
dence of telomere dysfunction has been observed early in
the progression of the disease (Chin et al., 2004; Meeker and
Argani, 2004; Tanaka et al., 2012). Furthermore, copy number
aberrations, of the type generated by telomere-dysfunction,
confer a poorer prognosis (Curtis et al., 2012). Given this, we
set out to use the telomere length thresholds below which
telomere fusion is detected in CLL, together with high-
resolution telomere length analysis, in a retrospective study
of tumour DNA from a cohort of breast cancer patients with
invasive ductal carcinoma (n ¼ 120). Our data show that avalue, Hazard Ratio (HR) and 95% confidence interval are indicated
r curve for overall survival using a telomere length of 2.26 kb to stratify
hort and plots the hazard ratios for overall survival for each threshold
east cancer cohort. Blue markers indicate significant HRs (P< 0.05),
Meier curve for overall survival using a telomere length of 2.60 kb to
usion threshold identifies a poor prognostic subset of breast
016/j.molonc.2015.02.003
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Figure 2 e Telomere dysfunction provides increased prognostic resolution for overall survival compared to the commonly used markers in breast
cancer. Kaplan Meier curves for overall survival of the same cohort of patients diagnosed with ductal breast carcinoma. (A) estrogen receptor (ER)
to stratify patients. (B) Progesterone receptor (PGR). (C) Human epidermal growth factor receptor 2 (HER2). (D) histological grade. (E)
Nottingham Prognostic Index (NPI). P value, Hazard Ratio (HR), Chi Squared value (c2) and 95% confidence interval are indicated on the plots
together with numbers at risk in each arm (N).
MO L E C U L A R O N C O L O G Y XXX ( 2 0 1 5 ) 1e8 5small subset of breast tumours exhibit telomere length pro-
files within the length ranges in which telomere fusion can
occur and these patients display a poor prognosis. These
data are consistent with the view that the progression to ma-
lignancy in breast cancer requires transition through a
telomere-driven crisis and that this facilitates clonal evolution
and progression.Please cite this article in press as: Simpson, K., et al., Telomere f
cancer patients, Molecular Oncology (2015), http://dx.doi.org/10.1Telomere length has previously been assessed as a prog-
nostic marker in breast cancer. Lu et al. used high throughput
qPCR in a cohort of breast tumours and found no association
with any of the clinical or pathological features of the disease
(Lu et al., 2011). Whereas a previous study determining telo-
mere content, not length, using slot blots showed that the
lower tertile of telomere content was prognostic for overallusion threshold identifies a poor prognostic subset of breast
016/j.molonc.2015.02.003
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Figure 3 e Telomere length in breast cancer is independent of ER, PGR, HER2 status, NPI score and grade. (A) Scatter plot displaying mean
XpYp telomere length of ER positive or negative breast cancers as indicated. P value derived from a ManneWhitney test is displayed above. The
telomere length thresholds that provide prognostic information are indicated with coloured lines, the upper limit 3 kb (pink) and the optimum
limit of 2.26 kb (purple). (B) Scatter plot displaying mean XpYp telomere length of PGR positive or negative breast cancers as indicated. (C)
Scatter plot displaying mean XpYp telomere length of HER2 positive or negative breast cancers as indicated. (D) Scatter plot displaying mean
XpYp telomere length according to grade. (E) Scatter plot displaying mean XpYp telomere length according to NPI score. (F) Scatter plot
displaying mean XpYp telomere length according to molecular sub-type, Luminal A (ERD and/or PRD, HER2L), Luminal B (ERD and/or
PRD, HER2D), HER2D/ERL (ERL, PRL, and HER2D) and Triple Negative (ERL, PRL, HER2L).
M O L E C U L A R O N C O L O G Y XXX ( 2 0 1 5 ) 1e86survival (Fordyce et al., 2006; Heaphy et al., 2007). Consistent
with the Lu et al. study, our data showed no prognostic signif-
icance when using the median telomere length of the cohort
as the cut off for long or short telomeres (Lu et al., 2011). How-
ever, when using the same telomere length threshold previ-
ously defined in CLL to stratify the patients, wePlease cite this article in press as: Simpson, K., et al., Telomere f
cancer patients, Molecular Oncology (2015), http://dx.doi.org/10.1demonstrated remarkable prognostic discrimination for over-
all survival in breast cancer patients. A small subset of pa-
tients with short telomeres within the telomere fusogenic
range had a median survival of 12 months with no patients
surviving beyond five years. In contrast, 88% of patients with
telomeres above the fusogenic range were alive at five years.usion threshold identifies a poor prognostic subset of breast
016/j.molonc.2015.02.003
MO L E C U L A R O N C O L O G Y XXX ( 2 0 1 5 ) 1e8 7The fusogenic threshold was independent of the commonly
used markers in breast cancer and was the dominant variable
in multivariate analysis. This study was limited in both in the
size of the cohort and the length of clinical follow up data
available and clearly our findings will require validation in a
larger cohort with a longer clinical follow-up. However these
data do indicate that high-resolution telomere length anal-
ysis, coupled with the telomere fusion threshold, identifies a
subset of patients a particularly poor prognosis. This group
of patients could not be identified with the commonly used
prognostic markers in breast cancer. Taken together our
data suggest that high-resolution telomere length analysis
could be a useful component in multivariate prognostic
algorithms.
Our data show that telomere shortening can be extensive
in breast tumours, yet this appears to occur in the presence
of telomerase, which is detected in the majority of breast tu-
mours analysed (Hiyama et al., 1996; Pearson et al., 1998).
However an absence of any relationship between the levels
of telomerase activity and telomere length has been reported
in Breast cancer (Lu et al., 2011) and other tumour types (Wang
et al., 2002). We have recently shown that short telomeres can
be detected in early stage lesions for example in colorectal
adenomatous polyps (Roger et al., 2013) and in chronic lym-
phocytic leukaemia prior to clinical progression (Lin et al.,
2010, 2014). Importantly these data also show that short telo-
meres, of the same length as that observed tumours, can also
be detected within the telomere length profiles of normal tis-
sue. These observations have allowed us to conclude that the
majority of telomere erosion may occur in the normal tissue
prior to the initiating event. This may also be the situation
in normal breast epithelium; consistent with this view, in
situ hybridization has revealed telomere shortening in subsets
of normal breast epithelium (Meeker et al., 2004a).
In addition to providing prognostic resolution, our
telomere-length data imply that telomere dysfunction is
important in the pathogenesis of breast cancer, a view that
is consistent with data from other laboratories (Chin et al.,
2004; Tanaka et al., 2012). Moreover BRCA1/2 breast tumours
with short telomeres have also been associated with higher
levels of apoptotic markers and p53 overexpression, consis-
tent with DNA repair defects and genomic instability
(Martinez-Delgado et al., 2013). Telomere fusion arises as
consequence of aberrant DNA repair activities at short telo-
meres and there is growing body of evidence to implicate
alternative non-homologous end joining (A-NHEJ) in this pro-
cess (Letsolo et al., 2010; Rai et al., 2010; Tankimanova et al.,
2012). Poly [ADP-ribose] polymerase 1 (PARP1), Ligase III and
to lesser extent Ligase I have been implicated in A-NHEJ
(Boboila et al., 2012; Simsek et al., 2011), these proteins, in
particular PARP1, have provided potential therapeutic targets
(Chen et al., 2008; Rouleau et al., 2010). Our data indicate the
intriguing possibility that breast tumours, exhibiting telo-
meres within the length range at which fusion is detected,
may be sensitive to agents targeted to the A-NHEJ pathway.
Telomere dysfunction has been implicated in the progres-
sion of numerous tumour types (Svenson and Roos, 2009), we
therefore considered that the telomeric parameters defined in
CLL may be applicable to other tumour types. Here we show
that this is the case for breast cancer and therefore our dataPlease cite this article in press as: Simpson, K., et al., Telomere f
cancer patients, Molecular Oncology (2015), http://dx.doi.org/10.1pinpoint an important biological limit threshold for telomere
length in both CLL and breast tumours; patients with telo-
meres below the telomere fusogenic mean exhibited a consis-
tently inferior clinical outcome. We therefore consider that
the telomere fusion threshold will be applicable to a broad
spectrum of tumour types.Funding
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